Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease - Wikidata - awgldk - TriplyDB

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

http://www.wikidata.org/entity/Q28196661

about

High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance Pharmacotherapy in the cardiac catheterization laboratory: evolution and recent developments Prasugrel Stent thrombosis: consider also low response to antiplatelets Optimizing platelet P2Y12 inhibition for patients undergoing PCI Discovering anti-platelet drug combinations with an integrated model of activator-inhibitor relationships, activator-activator synergies and inhibitor-inhibitor synergies Management standards for stable coronary artery disease in India.Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project).Cardiac purinergic signalling in health and disease Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement.Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent.Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.Constitutively released adenosine diphosphate regulates proplatelet formation by human megakaryocytes.Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics.Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.Overcoming aspirin resistance with loading clopidogrel earlier in elective percutaneous coronary intervention.Significance of clopidogrel resistance related to the stent-assisted angioplasty in patients with atherosclerotic cerebrovascular disease.Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options.A Study of Platelet Inhibition, Using a 'Point of Care' Platelet Function Test, following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction [PINPOINT-PPCI].Safety of the primary percutaneous coronary intervention strategy combining pre-hospital prasugrel, enoxaparin and in-hospital bivalirudin in acute ST-segment elevation myocardial infarction Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review.A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.Comparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial.Pharmacological antithrombotic adjuncts to percutaneous coronary intervention.Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives.Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.New antiplatelet agents for cardiovascular disease.P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.Effect of Oral Anti-platelet Regimens on Platelet Aggregation using Chronolog Light Transmittance Aggregometry in Coronary Heart Disease Patients: An Observational Study.Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.Prasugrel for the treatment of patients with acute coronary syndrome.Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.Update on oral antiplatelet therapy: principles, problems and promises.Long-term effect of chronic oral anticoagulation: focus on coronary artery disease.Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel.Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.Platelet P2Y12 receptor inhibition by thienopyridines: status and future.

P2860

Q26824850-6BD822F4-6F0E-4089-8478-D7EE04F09AC5 Q26862694-1CFD9491-3F6E-464F-8CFD-E27D56B68D56 Q28210429-773A0BB7-B750-4200-A3AA-6D816E512F9F Q28217585-B64E21F1-3CDE-4F83-AB47-2E499D9C1C58 Q28218094-1BFDC205-8916-4530-9EA8-E5BB43930847 Q28546587-1E80160D-174C-4D48-8818-4A7A2D2981B8 Q30239853-7650D8E0-4483-49A3-92E7-12DF14A2B363 Q30827217-9AE4B288-70B3-4451-900F-DC2E03BE91D3 Q33165093-5B3C6633-2808-42FD-B1BD-23953D899DD9 Q33554381-95967399-DDF8-41AA-A212-943DD3D88107 Q33561577-02F5D475-CB91-48E9-8E52-EE993672651C Q34043989-407AB3F7-2328-4AC2-805E-7BC228700BE7 Q34280678-2BC35C0F-BFF7-4D04-B2F2-1D3AFE52F60D Q34716730-184C692D-8894-48DA-9A06-1C914145F23F Q34771381-E84CC4F0-2450-47FA-B7AE-D1329B4195AF Q35141555-D68D645E-CF3D-4B27-A939-940D1214B9C5 Q35176063-BD9EB2AF-03A8-424A-B3BB-C1D48FED96F4 Q35752619-317F23C7-57DE-4E8B-8945-3B6BC7118A3B Q35797491-E4DFEE69-76DE-4908-A506-594A87659B5C Q35870016-089BC277-9078-4921-838B-3B9F1FA5D9C8 Q36090735-F24E68DA-EA34-48C6-8B27-2F3C75C537A0 Q36302146-53420678-68D8-4CFF-9870-7E167C716109 Q36649213-EE398B2E-6CC6-4AB6-8FC6-D1E12C8E6C59 Q36688145-64A9ADB7-EC6F-4A04-A1FF-31BDE2222A9F Q36787291-7B83833F-1E41-4170-BA5F-66D00DE13F7D Q36941850-7074A33B-41EA-4AD0-9EC2-CCBA31EBD053 Q37259929-A8D72318-9C62-482C-B705-4CE88809969B Q37304566-FF2098A7-6EE5-4573-9415-9B8D4C4AF5D4 Q37339517-D8166F35-A39A-4975-AEA6-A255301A04EC Q37380507-AB3EB225-53E0-4426-A253-D6EA449280F1 Q37429557-F192D775-D709-4094-A0C3-71D73815E7F9 Q37451509-0620CB9E-4D4F-4A75-8713-5578D4B6A00D Q37479088-3890D507-C237-460C-90E1-09F5CA35FAF8 Q37486601-1F797547-EBF1-44E5-A2EB-5EE2091DA39B Q37486605-6C700AF4-56AC-41CC-A4C1-B97265EA798D Q37486610-00BF46B1-B1CC-411A-97A9-5431455506F3 Q37498604-F63644B9-0C84-4FD7-9DAA-34A77CF53310 Q37552005-63D5545A-7CC4-4415-873A-65EDDABEB133 Q37562606-FFA043F4-2505-46F5-A141-4EF237AA8144 Q37579228-697F019E-CD42-4585-9022-004D830512E8

P2860

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

http://www.wikidata.org/entity/Q28196661

description

2006 nî lūn-bûn

@nan

2006 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Prasugrel achieves greater inh ...... stable coronary artery disease

@ast

Prasugrel achieves greater inh ...... stable coronary artery disease

@en

Prasugrel achieves greater inh ...... stable coronary artery disease

@nl

type

label

Prasugrel achieves greater inh ...... stable coronary artery disease

@ast

Prasugrel achieves greater inh ...... stable coronary artery disease

@en

Prasugrel achieves greater inh ...... stable coronary artery disease

@nl

prefLabel

Prasugrel achieves greater inh ...... stable coronary artery disease

@ast

Prasugrel achieves greater inh ...... stable coronary artery disease

@en

Prasugrel achieves greater inh ...... stable coronary artery disease

@nl

P1433

Q28196661-5D118E7C-9F14-48CB-9623-161B742D3D70

P1476

Q28196661-A49988FE-FA6C-4AA5-B2C2-CB5D846D35C9

P2093

Q28196661-1EFBDB69-76E4-4E10-A9A6-54F3A56418B2

Q28196661-403D450E-D324-418A-83E7-698606954B7B

Q28196661-59727030-2AEC-4DF6-8DDB-AA9560C8E4B9

Q28196661-603702E5-64FA-4F74-BA4D-CA01EB74191F

Q28196661-AC273824-532D-4B77-8451-CEBFA2121EC7

Q28196661-E723F78C-B6AE-43CB-AB91-A371645192CE

Q28196661-F46DBEAE-59DB-4909-9924-4DC7F33C7C80

P2860

Q28196661-0A6AB00E-F58D-4E79-BC61-4EC785E3DF12

Q28196661-11507F0F-3F56-482E-BD79-90CB70B0DE2F

Q28196661-2366F7C1-D5D0-4CF9-BA21-281D554FFFC0

Q28196661-25B00B23-2F23-45A8-8DB8-8EE0E01C864F

Q28196661-25EBBB8B-8236-4A3F-99BD-CA2F55A2797A

Q28196661-29FE7AF7-AA4D-41D4-A981-EF4309F8714D

Q28196661-471DDE3A-82DA-45C7-ABE4-253582A2AED6

Q28196661-6D0C6DF6-035F-433C-9703-5662AC41C364

Q28196661-720D4C0F-E592-4C63-B0DB-09012B121673

Q28196661-7210F4A7-189C-464B-990A-35986368BEE9

P304

Q28196661-B12CFDC5-D6D2-48E9-94DE-1CB840B69503

P31

Q28196661-1C5ADDB1-1A7E-4724-B3DF-558C24CC4997

P3181

Q28196661-510DAC4C-9634-49A9-8BF4-E4FD4CC5ABFE

P356

Q28196661-BCD87E38-AE09-4CB8-8192-6249D60EDA73

P407

Q28196661-34EC1260-1321-42E1-816E-6A2EB91E51E8

P433

Q28196661-24BB9D4E-A1F0-4687-9F3B-EAB091164A27

P478

Q28196661-3E4486FA-0267-4B0C-BA15-1DED6E3C9ACB

P50

Q28196661-5BE42466-6E08-4800-BB0C-D71E0EA4031E

Q28196661-D77AA7B1-B0BB-4E03-84F0-ED5543A420C4

P577

Q28196661-6A309B93-8BF3-4DEB-B98D-600D15EDF910

P5875

Q28196661-9B2EAFC3-CFDF-42C5-A528-59769DB54A38

P698

Q28196661-EEF7F705-F843-4D61-887F-3E7974A7713B

P921

Q28196661-19FE59CB-E5A7-4730-87B0-05CE9023905D

Q28196661-68C8F9A5-940D-4031-885C-90A90C21E414

Q28196661-7E48D7EF-1650-430F-B83C-B02D35F0EA78

P3181

P356

P1433

European Heart Journal

P1476

Prasugrel achieves greater inh ...... stable coronary artery disease

@en

P2093

Christelle Darstein

http://www.w3.org/2001/XMLSchema#string

Christopher D Payne

http://www.w3.org/2001/XMLSchema#string

Hideo Naganuma

http://www.w3.org/2001/XMLSchema#string

John T Brandt

http://www.w3.org/2001/XMLSchema#string

Joseph A Jakubowski

http://www.w3.org/2001/XMLSchema#string

Kenneth J Winters

http://www.w3.org/2001/XMLSchema#string

Tomas Jernberg

http://www.w3.org/2001/XMLSchema#string

P2860

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

Controversies in antiplatelet therapy for patients with cardiovascular disease

Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement

Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial

Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

Durability of platelet inhibition by clopidogrel

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation

P304

1166-73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4221154

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/EURHEARTJ/EHI877

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Agneta Siegbahn

P577

2006-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7158197

http://www.w3.org/2001/XMLSchema#string

P698

16621870

http://www.w3.org/2001/XMLSchema#string

P921